NBC Channel 12 News in Arizona Interviews Cannabis Science’s Dr. Melamede; Answering Questions & Discussing the New Documen...
March 30 2012 - 10:20AM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana) products, is
pleased to announce that Dr. Melamede was featured on NBC Channel
12 News in Arizona yesterday, March 29th, answering medical
questions and discussing the new documentary “Chronic Future -
Killing Cancer”, which will premier on April 5th, 2012, at the
Harkins Theater on Shea and Scottsdale Road in Scottsdale.
The documentary “Chronic Future - Killing Cancer” has been
receiving a lot of buzz and potential media coverage by TV
channels, news stations and radio stations. The first television
news channel to have the pleasure of interviewing Cannabis
Science’s own, Dr. Robert Melamede about this documentary, was NBC
Channel 12 News. The interview was aired yesterday March 29th at
4:30pm in Arizona. Dr. Melamede answered questions via Skype
regarding the effectiveness of medical cannabis, and discussed the
documentary, which he himself is featured in as well as Cannabis
Science patient’s one and three. Relating to use of medical
cannabis and it killing cancer, Dr. Robert Melamede stated, “People
are able to experiment on themselves, and are able to do that in a
relatively safe manner because of the extremely low toxicity of
cannabinoids and the main active ingredients in cannabis.” Also one
of the creators of the documentary Henry Miller appeared in studio
speaking about why he wanted to show the medical marijuana debate
in the documentary.
You can view this interview on the NBC Channel 12 News website,
http://www.azcentral.com/12news/ and search “Documentary Claims
Hemp Cures Cancer”, to learn more about the documentary and the use
and effectiveness of medical cannabis.
The documentary covers everything from the success in the use of
medical cannabis with different cancer patients, as well as the
unfortunate reality in which the federal government has made it
difficult for patients in every state, who need the use of
medicinal cannabis for a chronic disease or illness, to attain
their medicine without fear.
Cannabis Science is currently waiting to receive confirmation
from Henry Miller about numerous other media stations, to promote
this must see documentary and provide awareness to everyone about
cannabis itself.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.